COOCooper Companies (The)

$54.37-19% 1Y

$54.37

$53.7052 weeks$84.32

Is the price fair?

Fair

The yardsticks disagree: cheap against its own 5-year P/E range (10th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.

1 good, 1 to watch, 1 neutral

What the price assumes~+5% a year

Priced for ~5% a year FCF growth. Roughly in line with its three-year revenue growth of 6% a year.

Vs its own P/E rangecheaper than 90% of its own historyderived

Cheap vs its own history: P/E 18.6 vs a 38.1 median over 41 quarters (−51% vs median).

Vs sector (EV/EBIT)29.2×

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jul 31, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)middle of the market

FCF yieldmiddle of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What COO's price assumes

Cooper Companies (The) trades at 18.6× earnings against 39.6× for the median Medical Instruments & Supplies name, cheaper than its own group.

18.6

Trailing P/E · Medical Instruments & Supplies median 39.6 · cheaper than the typical name in its group

Price / sales: 3.03
Price / sales · today's price, trailing year to Jul 31, 2026
Free cash flow yield: 5.3%
Free cash flow yield · Medical Instruments & Supplies median 3.4%
Growth the price implies: +4.9%
Growth the price implies · The price pays for +4.9% free cash flow growth a year for a decade; the business has delivered +45% a year over the last three.